TY - JOUR T1 - Safety and Efficacy of Methylprednisolone Infiltration in Anserine Syndrome Treatment JO - Reumatología Clínica (English Edition) T2 - AU - Vega-Morales,David AU - Esquivel-Valerio,Jorge Antonio AU - Negrete-López,Roberto AU - Galarza-Delgado,Dionicio Ángel AU - Garza-Elizondo,Mario Alberto SN - 21735743 M3 - 10.1016/j.reumae.2011.10.009 DO - 10.1016/j.reumae.2011.10.009 UR - https://reumatologiaclinica.org/en-safety-efficacy-methylprednisolone-infiltration-in-articulo-S2173574312000317 AB - ObjectiveThe anserine syndrome is a common cause of knee pain. Infiltration with glucocorticoids has been evaluated in studies with low level of evidence and there are no published clinical trials to determine its usefulness. The objective of this study was to determine the efficacy and safety of the infiltration of methylprednisolone in the treatment of anserin syndrome. MethodsWe conducted a clinical trial in 58 adult patients with anserin syndrome, which presented intra-articular pathology ruled that reflected pain in the medial aspect of the knee. The WOMAC scale was assessed at baseline and patients were randomized to receive an infiltration of lidocaine plus 40mg methylprednisolone acetate (group 1) versus xylocaine plus distilled water (group 2). Both groups received 100mg of diclofenac sodium for 10 days. The WOMAC scale was applied at 4 weeks and adverse events were recorded. ResultsEquivalence was demonstrated in both groups for demographic variables and initial clinical evaluation. There was no statistical difference in the 3 domains of assessment of the baseline WOMAC score. The median baseline WOMAC in group 1 was 32 and in group 2 was 25.5 points. At 4 weeks it was 8 and 6.5 points, which corresponded to an improvement of 61.6% and 62.8%, respectively. ConclusionThe infiltration with methylprednisolone in anserin syndrome is not superior to placebo in patients taking diclofenac measured by the WOMAC scale at 4 weeks. The incidence of adverse events did not show any differences either. ER -